Detalhe da pesquisa
1.
Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment.
Xenobiotica
; 52(1): 65-78, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34761729
2.
An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Nat Chem Biol
; 13(4): 381-388, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28135235
3.
Quantitative Profiling of Combinational K27/K36 Modifications on Histone H3 Variants in Mouse Organs.
J Proteome Res
; 15(3): 1070-9, 2016 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26799478
4.
Absolute quantification of histone PTM marks by MRM-based LC-MS/MS.
Anal Chem
; 86(19): 9679-86, 2014 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25166916
5.
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.
J Med Chem
; 65(7): 5317-5333, 2022 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35352560
6.
Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain.
SLAS Discov
; 23(9): 930-940, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562800
7.
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.
J Med Chem
; 60(6): 2215-2226, 2017 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28092155